RxDoctor Payments Data

Daphne Rosales Barragan, MD

Family Medicine · Tucson, AZNPI 1952740862

Payments from drug & device makers

$650in general payments, 2019–2025

Across 27 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$187
  • Boston Scientific$107
  • Abbott$78
  • AstraZeneca$50
  • Amgen$47
  • Exact Sciences$36
  • plus $143 from 7 others

What the payments were for

  • Food & beverage$650100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$650 in reported general payments places this provider in the 65th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$172,543
Medicare patients
380
Services billed
4,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$85,506
OzempicSemaglutide66$82,061
XareltoRivaroxaban49$62,121
TrulicityDulaglutide18$36,945
JardianceEmpagliflozin26$33,969
MounjaroTirzepatide14$19,516
CreonLipase/Protease/Amylase12$18,127
LinzessLinaclotide18$16,938
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,918
Repatha SureclickEvolocumab13$8,302
Levothyroxine Sodium599$5,649
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,310
Atorvastatin Calcium540$4,660
Gabapentin243$4,554
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$85,50666 claims
Novo NordiskOzempic$24$82,06166 claims
GSKTrelegy Ellipta, Anoro Ellipta$187$19,22832 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$5,649599 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →